CSF2 and cancer: Recombinant NDV (MEDI5395) expressing granulocyte-macrophage colony-stimulating factor (GMCSF), based on the strain NDV-73T, is being evaluated with intravenous administration (NCT03889275) in conjunction with durvalumab in patients with various advanced malignant tumors (Burke et al., 2020).